Last reviewed · How we verify
NCT06142240
Efficacy of Two Therapeutic Exercise Modalities for Patients With Persistent COVID
NA trial testing exercise programe in Persistent COVID-19 in 40 participants. Status unknown.
1 April 2025
Quick facts
| Lead sponsor | Facultat de ciencies de la Salut Universitat Ramon Llull |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 June 2023 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- exercise programe
Conditions studied
- Persistent COVID-19 — all drugs for Persistent COVID-19 →
Sponsor
Facultat de ciencies de la Salut Universitat Ramon Llull
Who can join
Adults 18 to 60, any sex, with Persistent COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Symptoms of long-standing sequelae and complications of COVID-19, termed Long COVID19 or persistent COVID, have been reported worldwide. However, the etiology underlying the prolonged or fluctuating symptomatology is limited and there is no uniform and widely accepted definition.Patients describe persistent COVID as a fluctuating disease with variable and persistent symptoms.Most of the effects correspond to clinical symptoms such as fatigue, headache, arthralgias, hyposmia, gustatory sensations, etc. Fatigue is the most common and prolonged symptom of persistent COVID. Knowledge of the pathophysiological mechanisms of fatigue in COVID-19 disease, as well as the therapeutic approach, remains limited due to the relatively recent onset of this pathology. In particular, muscle strength training has been shown to improve muscle function and fatigue, not only during treatment, but also at long-term follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06142240
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Persistent COVID-19
Currently open trials in the same condition.
- NCT06766825 — Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) · Phase 2 · recruiting
- NCT06576102 — Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients · active not recruiting
Other Facultat de ciencies de la Salut Universitat Ramon Llull trials
Trials by the same sponsor.
- NCT06936579 — Cortical Effects of Peripheral Proprioceptive Stimulation on the Motor Evoked Potentials of the Limbs · NA · not yet recruiting
- NCT06951568 — Study of the Effect of Peripheral Somatosensory Stimulation on the Functionality of Patients With Cerebral Palsy and Red · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06142240 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Facultat de ciencies de la Salut Universitat Ramon Llull
- Last refreshed: 21 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06142240.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing